Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
FDF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4alpha,5-epoxy-17beta-hydroxy-3-oxoandrostane-2-carbonitrile
2. Modrenal
3. Win 24,540
1. 13647-35-3
2. Modrenal
3. Vetoryl
4. Desopan
5. Modrastane
6. Trilostanum
7. Trilostano
8. Win-24540
9. Win 24,540
10. Chebi:32260
11. L0fpv48q5r
12. Win 24540
13. Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4alpha,5alpha,17beta)-
14. Nsc-758904
15. Dsstox_cid_3706
16. Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4a,5a,17b)-
17. Dsstox_rid_77157
18. Dsstox_gsid_23706
19. (1ar,4ar,4bs,6as,7s,9as,9bs,11as)-2,7-dihydroxy-4a,6a-dimethyl-1a,4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11-tetradecahydrocyclopenta[7,8]phenanthro[1,10a-b]oxirene-3-carbonitrile
20. (1s,2r,6r,8s,11s,12s,15s,16s)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.0^{2,8}.0^{6,8}.0^{12,16}]octadec-4-ene-4-carbonitrile
21. Modrenal (tn)
22. (1ar,4ar,4bs,6as,7s,9as,9bs,11as)-2,7-dihydroxy-4a,6a-dimethyl-1a,4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11-tetradecahydrocyclopenta[7,8]phenanthro[1,10a-b]oxirene-3-carbonitrile.
23. (1s,2r,6r,8s,11s,12s,15s,16s)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.02,8.06,8.012,16]octadec-4-ene-4-carbonitrile
24. Desopan (tn)
25. Cas-13647-35-3
26. Trilostane (jan/usan)
27. Trilostanum [inn-latin]
28. Trilostano [inn-spanish]
29. Unii-l0fpv48q5r
30. Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4.alpha.,5.alpha.,17.beta.)-
31. Trilostane [usan:inn:ban:jan]
32. Ncgc00274061-01
33. Einecs 237-133-0
34. Mfcd00199295
35. Win 24450
36. Trilostane [mi]
37. Trilostane [inn]
38. Trilostane [jan]
39. Trilostane [usan]
40. Trilostane [vandf]
41. (4alpha,5alpha,17beta)-3,17-dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile
42. Schembl7517
43. Trilostane [mart.]
44. Trilostane [who-dd]
45. Gtpl6850
46. Trilostane [green Book]
47. Chembl1200907
48. Dtxsid9023706
49. Trilostane [orange Book]
50. Trilostane, >=98% (hplc)
51. 4.alpha.,5-epoxy-3,17.beta.-dihydroxy-5.alpha.-androst-2-ene-2-carbonitrile
52. Hms3884a15
53. Bcp04132
54. Tox21_112454
55. Tox21_302406
56. 4-alpha,5-epoxy-3,17-dihydroxy-5-alpha-androst-2-ene-2-carbonitrile
57. Ac-927
58. Bdbm50247882
59. S1404
60. 3,17beta-dihydroxy-4alpha,5-epoxy-5alpha-androst-2-ene-2-carbonitrile
61. 4alpha,5-epoxy-3,17beta-dihydroxy-5alpha-androst-2-ene-2-carbonitrile
62. Akos015964043
63. Akos032947221
64. Tox21_112454_1
65. Zinc100038546
66. Ccg-267803
67. Cs-1707
68. Db01108
69. Ks-1414
70. Nsc 758904
71. (2-alpha,4-alpha,5-alpha,17-beta)-4,5-epoxy-17-hydroxy-3-oxoandrostane-2-carbonitrile
72. 4-alpha-5-epoxy-17-beta-hydroxy-3-oxo-5-alpha-androstane-2-alpha-carbonitrile
73. Androstane-2-carbonitrile, 4,5-epoxy-17-hydroxy-3-oxo-, (2-alpha,4-alpha,5-alpha,17-beta)-
74. Ncgc00255201-01
75. Hy-14281
76. Bcp0726000098
77. D01180
78. Ab01274788-01
79. Ab01274788_02
80. 647t353
81. A886681
82. Q907313
83. Q-201884
84. Z1563146079
85. Trilostane; 13647-35-3; Vetoryl; Modrenal; Modrastane
86. (4a,5a,17b)-3,17-dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile
87. 5-alpha-androstane-2-alpha-carbonitrile, 4-alpha,5-epoxy-17-beta-hydroxy-3-oxo-
Molecular Weight | 329.4 g/mol |
---|---|
Molecular Formula | C20H27NO3 |
XLogP3 | 2.9 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 0 |
Exact Mass | 329.19909372 g/mol |
Monoisotopic Mass | 329.19909372 g/mol |
Topological Polar Surface Area | 76.8 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 692 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 8 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Used in the treatment of Cushing's syndrome. It is normally used in short-term treatment until permanent therapy is possible.
Trilostane blocks an enzyme involved in the production of several steroids including cortisol. Inhibiting this enzyme inhibits the production of cortisol. In Cushing's syndrome, the adrenal gland overproduces steroids. Although steroids are important for various functions of the body, too much can cause problems. Trilostane reduces the amount of steroids produced by the adrenal gland. This product was withdrawn from the U.S. market in April 1994.
Abortifacient Agents, Steroidal
Steroidal compounds with abortifacient activity. (See all compounds classified as Abortifacient Agents, Steroidal.)
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
H - Systemic hormonal preparations, excl. sex hormones and insulins
H02 - Corticosteroids for systemic use
H02C - Antiadrenal preparations
H02CA - Anticorticosteroids
H02CA01 - Trilostane
Hepatic.
8 hours.
Trilostane produces suppression of the adrenal cortex by inhibiting enzymatic conversion of steroids by 3-beta-hydroxysteroid dehydrogenase/delta 5,4 ketosteroid isomerase, thus blocking synthesis of adrenal steroids.
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19686
Submission : 2006-08-14
Status : Active
Type : II
NDC Package Code : 64918-0725
Start Marketing Date : 2014-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6092
Submission : 1985-11-13
Status : Inactive
Type : II
NDC Package Code : 26251-0005
Start Marketing Date : 2019-08-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 52128-165
Start Marketing Date : 2013-03-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (5kg/5kg)
Marketing Category : BULK INGREDIENT
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
About the Company : Established in 1982, ChemWerth is a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company. ChemWerth offers cGMP-quality APIs ...
About the Company : Suanfarma founded in 1993, is a B2B life science partner committed to health & innovation by developing, manufacturing, & distributing high-quality APIs for the pharmaceutical indu...
About the Company : ASG Biochem Private Limited at Ganganagar near Kolkata, West Bengal, India, is a bulk API manufacturing company of the New Delhi based diversified APEEJAY STYA GROUP. The unit acqu...
About the Company : Guangzhou Topwork Chemical Co., Ltd. Specializes in manufacturing corticosteroid and relative intermediates. We provide high quality products and excellent service to our clients a...
About the Company : The Quality Assurance department is the Guardian of Quality within the Company. We have a team dedicated to identifying and implementing new ICH guidelines. Our team is prepared ...
About the Company : Symbiotica is a Manufacturer of APIs from Malaysia with a cGMP Steroidal facility at Kulim, a Pioneer status from Malaysian Industrial Development Authority and P.I.C/S & W.H.O GMP...
About the Company : Founded in 2001, Tianjin Pacific Chemical & Pharmaceutical Co.,Ltd (TPCPC) is located in Jinnan Development Zone of Tianjin,and it covers an area of more than 3900 ㎡ including a ...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?